help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perlino, E.
Right arrow Articles by Languino, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perlino, E.
Right arrow Articles by Languino, L. R.
(American Journal of Pathology. 2000;157:1727-1734.)
© 2000 American Society for Investigative Pathology


Regular Articles

Regulation of mRNA and Protein Levels of ß1 Integrin Variants in Human Prostate Carcinoma

Elda Perlino*, Mariarosaria Lovecchio*, Rosa A. Vacca*, Mara Fornaro{dagger}, Loredana Moro{dagger}, Pasquale Ditonno{ddagger}, Michele Battaglia{ddagger}, Francesco P. Selvaggi{ddagger}, Mauro G. Mastropasqua§, Pantaleo Bufo§ and Lucia R. Languino{dagger}

From the Center of Study on Mitochondria and Energy Metabolism,*
Consiglio Nazionele delle Ricerche, Bari, Italy; the Chair of Urology{ddagger}
and the Institute of Pathological Anatomy,§
School of Medicine, University of Bari, Bari, Italy; and the Department of Pathology,{dagger}
Yale University School of Medicine, New Haven, Connecticut

Alterations of integrin expression levels in cancer cells correlate with changes in invasiveness, tumor progression, and metastatic potential. The ß1C integrin, an alternatively spliced form of the human ß1 integrin, has been shown to inhibit prostate cell proliferation. Furthermore, ß1C protein levels were found to be abundant in normal prostate glandular epithelium and down-regulated in prostatic adenocarcinoma. To gain further insights into the molecular mechanisms underlying abnormal cancer cell proliferation, we have studied ß1C and ß1 integrin expression at both mRNA and protein levels by Northern and immunoblotting analysis using freshly isolated neoplastic and normal human prostate tissue specimens. Steady-state mRNA levels were evaluated in 38 specimens: 33 prostatic adenocarcinomas exhibiting different Gleason’s grade and five normal tissue specimens that did not show any histological manifestation of benign prostatic hypertrophy. Our results demonstrate that ß1C mRNA is expressed in normal prostate and is significantly down-regulated in neoplastic prostate specimens. In addition, using a probe that hybridizes with all ß1 variants, mRNA levels of ß1 are found reduced in neoplastic versus normal prostate tissues. We demonstrate that ß1C mRNA down-regulation does not correlate with either tumor grade or differentiation according to Gleason’s grade and TNM system evaluation, and that ß1C mRNA levels are not affected by hormonal therapy. In parallel, ß1C protein levels were analyzed. As expected, ß1C is found to be expressed in normal prostate and dramatically reduced in neoplastic prostate tissues; in contrast, using an antibody to ß1 that recognizes all ß1 variants, the levels of ß1 are comparable in normal and neoplastic prostate, thus indicating a selective down-regulation of the ß1C protein in prostate carcinoma. These results demonstrate for the first time that ß1C and ß1 mRNA expression is down-regulated in prostate carcinoma, whereas only ß1C protein levels are reduced. Our data highlight a selective pressure to reduce the expression levels of ß1C, a very efficient inhibitor of cell proliferation, in prostate malignant transformation.





This article has been cited by other articles:


Home page
Cancer Res.Home page
H. L. Goel, L. Moro, J. E. Murphy-Ullrich, C.-C. Hsieh, C.-L. Wu, Z. Jiang, and L. R. Languino
{beta}1 Integrin Cytoplasmic Variants Differentially Regulate Expression of the Antiangiogenic Extracellular Matrix Protein Thrombospondin 1
Cancer Res., July 1, 2009; 69(13): 5374 - 5382.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H. L. Goel, J. Li, S. Kogan, and L. R Languino
Integrins in prostate cancer progression
Endocr. Relat. Cancer, September 1, 2008; 15(3): 657 - 664.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
A. Gattelli, M. N. Zimberlin, R. P. Meiss, L. H. Castilla, and E. C. Kordon
Selection of Early-Occurring Mutations Dictates Hormone-Independent Progression in Mouse Mammary Tumor Lines
J. Virol., November 15, 2006; 80(22): 11409 - 11415.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Lee, M. A. Skinner, H.-b. Guo, A. Sujan, and M. Pierce
Expression of the Vacuolar H+-ATPase 16-kDa Subunit Results in the Triton X-100-insoluble Aggregation of {beta}1 Integrin and Reduction of Its Cell Surface Expression
J. Biol. Chem., December 17, 2004; 279(51): 53007 - 53014.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Moro, E. Perlino, E. Marra, L. R. Languino, and M. Greco
Regulation of {beta}1C and {beta}1A Integrin Expression in Prostate Carcinoma Cells
J. Biol. Chem., January 16, 2004; 279(3): 1692 - 1702.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Lovecchio, E. Maiorano, R. A. Vacca, G. Loverro, M. Fanelli, L. Resta, S. Stefanelli, L. Selvaggi, E. Marra, and E. Perlino
{beta}1C Integrin Expression in Human Endometrial Proliferative Diseases
Am. J. Pathol., December 1, 2003; 163(6): 2543 - 2553.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
R. A. Vacca, E. Marra, G. Loverro, E. Maiorano, A. Napoli, M. Lovecchio, L. Selvaggi, and E. Perlino
Differential Expression of {beta}1c Integrin Messenger Ribonucleic Acid and Protein Levels in Human Endometrium and Decidua during the Menstrual Cycle and Pregnancy
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 720 - 729.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society for Investigative Pathology.